Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer
Terry Hermiston
Terry Hermiston
Published May 1, 2000
Citation Information: J Clin Invest. 2000;105(9):1169-1172. https://doi.org/10.1172/JCI9973.
View: Text | PDF
Perspective

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

  • Text
  • PDF
Abstract

Authors

Terry Hermiston

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Theoretical advantages of replication-selective, transgene-expressing on...
Theoretical advantages of replication-selective, transgene-expressing oncolytic viruses. As several articles in this series show, cytolytic viruses can be engineered that exploit the quirks of cancer cells and spare neighboring tissues. The melding of this technology with gene therapy offers the prospect of safe treatments, enhanced killing of tumor cells, and subtle control over immune responses to tumor cells or viral antigens.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts